BiomX (NYSEMKT:PHGE) Stock Price Down 1%

BiomX Inc. (NYSEMKT:PHGE) fell 1% on Tuesday . The stock traded as low as $1.00 and last traded at $1.01. 57,623 shares changed hands during trading, a decline of 16% from the average session volume of 68,601 shares. The stock had previously closed at $1.02.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of BiomX in a research note on Friday, August 16th.

BiomX Trading Down 1.0 %

The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The stock has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $0.46. The firm has a market capitalization of $70.50 million, a P/E ratio of -1.66 and a beta of 1.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC purchased a new stake in BiomX Inc. (NYSEMKT:PHGE) during the first quarter, according to its most recent filing with the SEC. The firm purchased 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX at the end of the most recent quarter. 40.57% of the stock is currently owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.